Saudi FDA: Working with Industry to Improve the Reporting of Adverse Reactions
Add bookmark
Saudi FDA: Working with Industry to Improve the Reporting of Adverse Reactions
Add bookmarkIn this interview Dr. Nasser Al-Qahtani, Head, Adverse Drug Reactions Evaluation Department Saudi FDA speaks to Andrea Charles from Pharma IQ, about the Saudi FDA pharmacovigilance system and what new guidelines he predicts will be areas for discussion amongst pharma/bio companies in 2012. Dr. Nasser Al-Qahtani shares his insights on the impact of social media on the pharmacovigilance system and the initiatives the Saudi FDA are planning to implement to establish the importance of pharmacovigilance for the safety of the patient.
[inlinead]
Have Your Say
Rate this feature and give us your feedback in the comments section below
Tags:
Nasser Al-Qahtani
Saudi FDA
drug safety
drug safety MENA
pharmacovigilance
adverse reactions
adverse errors
adverse event reporting
